Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Strong Buy

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Buy

A

Novo-Nordisk A/S (NVO)

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/09/1981

Market Cap

603,636,840,459

Shares Outstanding

3,435,130,000

Weighted SO

4,457,312,846

Total Employees

N/A

Upcoming Earnings

08/07/2024

Similar Tickers

REGN --.--%

CRSP --.--%

SRPT --.--%

NTLA --.--%

MRNA --.--%

CVAC --.--%

NVAX --.--%

CWBR --.--%

RETA --.--%

Beta

0.1310

Last Div

1.4400

Range

86.96-148.15

Chg

-1.7370

Avg Vol

4150941

Mkt Cap

603636840459

Exch

NYSE

Country

DK

Phone

45 44 44 88 88

DCF Diff

-39.2528

DCF

174.5428

Div Yield

0.0042

P/S

15.8397

EV Multiple

31.2358

P/FV

36.2936

Div Yield %

0.4238

P/E

45.4274

PEG

2.5279

Payout

0.4671

Current Ratio

0.9446

Quick Ratio

0.7511

Cash Ratio

0.2811

DSO

94.0260

DIO

332.4383

Op Cycle

426.4643

DPO

272.1155

CCC

154.3488

Gross Margin

0.8453

Op Margin

0.4326

Pretax Margin

0.4377

Net Margin

0.3484

Eff Tax Rate

0.2040

ROA

0.2434

ROE

0.8750

ROCE

0.6151

NI/EBT

0.7960

EBT/EBIT

1.0117

EBIT/Rev

0.4326

Debt Ratio

0.1545

D/E

0.5071

LT Debt/Cap

0.3144

Total Debt/Cap

0.3365

Int Coverage

30.1437

CF/Debt

2.0213

Equity Multi

3.2828

Rec Turnover

3.8819

Pay Turnover

1.3413

Inv Turnover

1.0979

FA Turnover

2.3459

Asset Turnover

0.6985

OCF/Share

25.8730

FCF/Share

14.8119

Cash/Share

14.0552

OCF/Sales

0.4470

FCF/OCF

0.5725

CF Coverage

2.0213

ST Coverage

21.1544

CapEx Coverage

2.3391

Div&CapEx Cov

1.2633

P/BV

36.2936

P/B

36.2936

P/S

15.8397

P/E

45.4274

P/FCF

61.8941

P/OCF

35.4087

P/CF

35.4087

PEG

2.5279

P/S

15.8397

EV Multiple

31.2358

P/FV

36.2936

DPS

0.5735

Latest Headlines (EST)

GlobeNewswire Inc. Jul 24, 02:57 HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS The Motley Fool Jul 21, 01:24 A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money GlobeNewswire Inc. Jul 19, 21:19 ROSEN, LEADING TRIAL ATTORNEYS, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS GlobeNewswire Inc. Jul 17, 02:43 HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS GlobeNewswire Inc. Jul 16, 02:09 HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS GlobeNewswire Inc. Jul 11, 18:45 ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS GlobeNewswire Inc. Jul 11, 00:57 ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS GlobeNewswire Inc. Jul 10, 02:39 HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS The Motley Fool Jul 09, 22:16 3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly GlobeNewswire Inc. Jul 09, 02:13 HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS GlobeNewswire Inc. Jul 06, 17:17 HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges HIMS Investors with Losses to Contact the Firm GlobeNewswire Inc. Jul 03, 23:41 Robbins LLP Urges HIMS Stockholders with Large Losses to Contact the Firm for Information About the Class Action Pending Against Hims & Hers Health, Inc. GlobeNewswire Inc. Jul 01, 23:49 INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Hims & Hers Health, Inc. (NYSE: HIMS) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm GlobeNewswire Inc. Jul 01, 01:00 HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm GlobeNewswire Inc. Jun 30, 21:45 ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS GlobeNewswire Inc. Jun 26, 01:19 HIMS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead the Hims & Hers Class Action Lawsuit GlobeNewswire Inc. Jun 23, 21:49 Hims & Hers Health, Inc. (HIMS) Shares Crash After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy, Faces Investor Scrutiny – Hagens Berman GlobeNewswire Inc. Jun 22, 19:35 Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress GlobeNewswire Inc. Jun 20, 23:38 Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA GlobeNewswire Inc. Jun 20, 23:34 Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.13 03/22/2024 01/31/2024 03/25/2024 04/02/2024
0.13 08/18/2023 08/10/2023 08/21/2023 08/29/2023
0.17 03/24/2023 02/02/2023 03/27/2023 04/04/2023
0.08 08/12/2022 08/04/2022 08/15/2022 08/23/2022
0.15 03/25/2022 03/02/2022 03/28/2022 04/05/2022
0.09 08/16/2021 08/06/2021 08/17/2021 08/25/2021
0.15 03/26/2021 02/23/2021 03/29/2021 04/07/2021
0.08 08/14/2020 08/06/2020 08/17/2020 08/25/2020
0.23 03/27/2020 02/06/2020 03/30/2020 04/07/2020
0.07 08/16/2019 08/09/2019 08/19/2019 08/27/2019
0.12 03/22/2019 11/30/-0001 03/25/2019 04/02/2019
0.07 08/17/2018 08/09/2018 08/20/2018 08/28/2018
0.11 03/23/2018 02/05/2018 03/26/2018 04/03/2018
0.07 08/17/2017 08/10/2017 08/21/2017 08/29/2017
0.10 03/23/2017 02/07/2017 03/27/2017 04/04/2017
0.07 08/11/2016 08/08/2016 08/15/2016 08/23/2016
0.15 03/18/2016 02/16/2016 03/22/2016 03/30/2016
0.11 03/19/2015 11/30/-0001 11/30/-0001 03/31/2015
0.15 03/21/2014 03/17/2014 03/25/2014 04/02/2014
0.55 03/21/2013 02/27/2013 03/25/2013 04/02/2013
0.44 03/22/2012 11/30/-0001 11/30/-0001 04/03/2012
0.34 03/24/2011 11/30/-0001 11/30/-0001 04/05/2011
0.25 03/25/2010 11/30/-0001 11/30/-0001 11/30/-0001
0.19 03/19/2009 11/30/-0001 11/30/-0001 11/30/-0001
0.18 03/13/2008 11/30/-0001 11/30/-0001 11/30/-0001
0.21 03/08/2007 11/30/-0001 11/30/-0001 03/20/2007
0.15 03/09/2006 11/30/-0001 11/30/-0001 11/30/-0001
0.15 03/10/2005 11/30/-0001 11/30/-0001 11/30/-0001
0.12 03/17/2004 11/30/-0001 11/30/-0001 11/30/-0001
0.09 03/26/2003 11/30/-0001 11/30/-0001 11/30/-0001
0.06 03/13/2002 11/30/-0001 11/30/-0001 11/30/-0001
0.13 03/21/2001 11/30/-0001 11/30/-0001 11/30/-0001
0.08 11/17/2000 11/30/-0001 11/30/-0001 11/30/-0001
0.10 03/24/2000 11/30/-0001 11/30/-0001 11/30/-0001
0.07 03/25/1999 11/30/-0001 11/30/-0001 11/30/-0001
0.07 03/27/1998 11/30/-0001 11/30/-0001 11/30/-0001
0.05 04/25/1997 11/30/-0001 11/30/-0001 11/30/-0001
0.04 05/01/1996 11/30/-0001 11/30/-0001 11/30/-0001
0.03 04/24/1996 11/30/-0001 11/30/-0001 11/30/-0001
0.03 04/24/1995 11/30/-0001 11/30/-0001 11/30/-0001
0.02 04/26/1994 11/30/-0001 11/30/-0001 11/30/-0001
0.02 04/22/1994 11/30/-0001 11/30/-0001 11/30/-0001
0.09 04/22/1993 11/30/-0001 11/30/-0001 11/30/-0001
0.10 04/28/1992 11/30/-0001 11/30/-0001 11/30/-0001
0.08 04/19/1991 11/30/-0001 11/30/-0001 11/30/-0001
0.10 04/23/1990 11/30/-0001 11/30/-0001 11/30/-0001
0.08 04/21/1989 11/30/-0001 11/30/-0001 11/30/-0001
0.09 04/21/1988 11/30/-0001 11/30/-0001 11/30/-0001
0.07 04/20/1987 11/30/-0001 11/30/-0001 11/30/-0001
0.06 04/21/1986 11/30/-0001 11/30/-0001 11/30/-0001
0.04 04/19/1985 11/30/-0001 11/30/-0001 11/30/-0001
0.05 04/13/1984 11/30/-0001 11/30/-0001 11/30/-0001
0.05 04/13/1983 11/30/-0001 11/30/-0001 11/30/-0001
0.01 04/23/1982 11/30/-0001 11/30/-0001 11/30/-0001